Yahoo! Finance Canada report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
Why MNKD Stock surged +4.29% Today — RQD Quant Desk Flash
MannKind Corporation (MNKD) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is MNKD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, MannKind Corporation (NASDAQ: MNKD) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $3.65 (+4.29% 1D, market cap $1.13B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, MNKD ranks #200 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does MNKD compare to AVLN and AMPH in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MNKD carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of 92.3%, and ROIC of 54.5%. By comparison, AVLN (Avalyn Pharma Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $1.14B) and AMPH (Amphastar Pharmaceuticals Inc.) posts a B grade (72/100 RQD, P/E 11.7x, ROIC 9.0%, cap $1.18B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while MNKD leads on capital efficiency (54.5% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for MNKD?
▼
Per MNKD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000899460), MannKind Corporation generated $349.0M in revenue (+22.2% YoY), $5.9M in net income, and $13.7M in free cash flow against $792.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 3.9% FCF Margin ($13.7M FCF) & 92.3% Gross Margin
SEC Form 4 / 13F Thermometer: 65% Net Buy • Disciplined Float (-0.32% YoY Shares)
Macro rate sensitivity & RSI-14 (55.6) create a -12 pt regime headwind
⚔️ Adversarial Opposing Case: Why the MNKD Bull Thesis Could Fail
Even with a 56/100 (D+) score, MNKD faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($3.56) or 200D SMA ($3.71) invalidates the momentum regime and cuts Target Base ($3.62) toward Bear Floor ($2.82).
Why MNKD Stock surged +4.29% Today — RQD Quant Desk Flash
MannKind Corporation (MNKD) surged +4.29% to $3.65, trading at 33% of its 52-week range ($2.23 – $6.51). Stretched risk/reward at current multiples (55% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 33% of its 52-week range ($2.23 – $6.51) with RSI-14 at 55.6 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.4% around $3.65 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 92.3% gross margin and $13.7M annual free cash flow.
Yahoo! Finance Canada report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
The Manila Times report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
MannKind has had a rough stretch in 2026, with the share price down 37.5% year to date, which puts fresh focus on whether the current US$3.50 level lines up with what its cash flows can support. With revenue now more hea
MannKind (NASDAQ:MNKD) Chief Executive Officer Mike Castagna said the company is advancing an inhaled version of nintedanib into a global Phase 2 study for idiopathic pulmonary fibrosis, or IPF, following early safety an
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MNKD)
- ✓Walkthrough of MNKD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
MNKD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +22.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MNKD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MNKD. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MNKD)
1. Head-to-Head Health Care Peer Comparison (MNKD vs. AVLN, AMPH, VSTM, JANX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, MannKind Corporation (MNKD) ranks #200 by composite RQD confidence (56/100, grade D+) and #342 by equity capitalization ($1.13B). Within this direct 5-issuer industry benchmark cohort, AMPH leads on earnings valuation at 11.7x trailing P/E, while MNKD leads on capital efficiency and profitability with 54.5% ROIC and 92.3% gross margin. AMPH currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with MNKD at 56/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MNKD
ACTIVE
MannKind Corporation | D+ | 56/100 | — | 92.3% | 54.5% | +4.29% | $1.13B | Benchmark Subject |
| AVLN Avalyn Pharma Inc. | D | 44/100 | — | — | — | -0.12% | $1.14B | /avln-vs-mnkd → |
| AMPH Amphastar Pharmaceuticals Inc. | B | 72/100 | 11.7x | 49.5% | 9.0% | -2.49% | $1.18B | /amph-vs-mnkd → |
| VSTM Verastem Inc. | D- | 36/100 | — | — | -35.0% | -1.64% | $1.18B | /vstm-vs-mnkd → |
| JANX Janux Therapeutics Inc. | D- | 37/100 | — | — | -13.8% | -0.06% | $1.07B | /janx-vs-mnkd → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000899460In its most recent audited fiscal period (FY2025, filed 2025-12-31), MannKind Corporation (MNKD) reported GAAP revenue of $349.0M (+22.2% vs. FY2024 revenue of $285.5M , and +75.4% cumulative change since FY2023) , GAAP net income of $5.9M, operating cash flow of $18.3M, and free cash flow of $13.7M (-58.3% YoY). On the balance sheet, MNKD closed FY2025 with $792.2M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $349.0M | $5.9M | $18.3M | $13.7M | $792.2M | — |
| FY2024 (FY) | 2024-12-31 | $285.5M | $27.6M | $42.5M | $32.8M | $393.8M | — |
| FY2023 (FY) | 2023-12-31 | $199.0M | -$11.9M | $34.1M | $34.1M | — | — |
3. MNKD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs MNKD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, MannKind Corporation (NASDAQ: MNKD) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $3.65 (+4.29% 1D, market cap $1.13B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, MNKD ranks #200 in composite RQD confidence.
How does MNKD compare to AVLN and AMPH in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MNKD carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of 92.3%, and ROIC of 54.5%. By comparison, AVLN (Avalyn Pharma Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $1.14B) and AMPH (Amphastar Pharmaceuticals Inc.) posts a B grade (72/100 RQD, P/E 11.7x, ROIC 9.0%, cap $1.18B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while MNKD leads on capital efficiency (54.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for MNKD?
Per MNKD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000899460), MannKind Corporation generated $349.0M in revenue (+22.2% YoY), $5.9M in net income, and $13.7M in free cash flow against $792.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is MNKD trading relative to its 50-day, 200-day, and 52-week technical levels?
MNKD last traded at $3.65 (+4.29% on volume of 3,175,147 shares), positioning the stock +2.53% above its 50-day simple moving average ($3.56) and -1.62% below its 200-day simple moving average ($3.71). Across its 52-week range of $2.23 to $6.51, MNKD sits at the 33.2% percentile with a 14-day RSI of 55.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±10.4% ($3.27 to $4.03).
MNKD — MannKind Corporation: What the Facts Mean to a Prospective Investor
1. Roarable Rating Brief: What This Means to a Prospective Investor
MNKD scores 55 out of 100 (letter grade D+), with the verdict "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:
- Fundamental Cash Engine (14/20): this pillar reflects ROIC of 54.5% and an FCF yield of 1.22%. The high ROIC contrasts with a thin 1.22% FCF yield, meaning the return on invested capital is not translating into proportionate cash returns to a buyer at the current price.
- Whale / 13F Flow (8/20): institutional accumulation and options positioning score weakly.
- Insider Conviction (13/20): SEC Form 4 and Congressional PTR cluster flow score moderately. Individual transactions are not itemized in the source data.
- Macro Regime Fit (8/20): beta of 1.0 and sector sensitivity score weakly, indicating limited defensive character relative to the market.
- Forensic Balance Sheet (12/20): Altman Z of 0.2 is a distress-zone reading, Piotroski F of 7/9 is a relatively healthy signal, and Debt/Equity of 0.5 is moderate. The conflict between a distressed Altman reading and a strong Piotroski reading is a key tension for an investor to weigh.
For a prospective investor evaluating the stock today, the rating implies that upside depends on the cash engine converting into free cash flow and on the balance sheet stabilizing, while the weak macro-fit and flow scores suggest limited institutional tailwind. The 55 score and "Trim" verdict frame the stock as one where risk currently outweighs the visible fundamental support.
2. Business Model, Unit Margins & SEC Financial Trajectory
MannKind Corporation (MNKD) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry..1B. Reported revenue for FY 2025 was $349.0M.
Per the market data, gross margin is 92.3%, operating margin 11.1%, and net margin 1.7%, with ROIC at 54.5%. The Altman Z-Score is 0.2 and the Piotroski F-Score is 7/9, with Debt/Equity at 0.5. Revenue grew from $199.0M in FY 2023 to $349.0M in FY 2025, while net income fell from $27.6M in FY 2024 to $5.9M in FY 2025. Cash rose from $46.3M to $74.9M over the same span.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case: ROIC of 54.5% and cash rising from $46.3M to $74.9M indicate the operating engine is generating returns on capital despite a weak overall rating. With Fundamental Cash Engine at 14/20 (ROIC 54.5%, FCF yield 1.22%) and Institutional Whale Flow at 9/20, sustained execution supports upside toward the top of the $2.23 – $6.51 52-week range.
- 🐻 Primary Bear Case: An Altman Z-Score of 0.2 combined with net income falling to $5.9M in FY 2025 signals financial distress risk alongside a 1.22% FCF yield. Investors must weigh current valuation and 24.6x EV/EBITDA against 11.1% operating margins and a 1.00 macro beta if sector demand softens.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are —
- Key Question #1: What are the reported EPS and trailing P/E figures, given that the financials table lists EPS as N/A and P/E as unavailable?
- Key Question #2: What is the company's debt balance, given that debt is N/A across all reported periods despite a stated Debt/Equity of 0.5?
- Key Question #3: Why did net income decline from $27.6M in FY 2024 to $5.9M in FY 2025 while revenue and operating income moved in differing directions?
MNKD Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for MannKind Corporation (MNKD) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
The Manila Times report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.
MNKD Bull vs. Bear Conversation Board — What's Your Call at $3.65?
ROIC of 54.5% and cash rising from $46.3M to $74.9M indicate the operating engine is generating returns on capital despite a weak overa
Don't sleep on MNKD's setup in Health Care. ROIC of 54.5% and cash rising from $46.3M to $74.9M indicate the operating engine is generating returns on capital despite a weak overall rating.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (56/100) backs up the fundamental quality.
@MidwestValue Agree on the RQD 56/100 quality, though with 1.0 beta I'm scaling in with half-size at $3.50 and keeping dry powder in case we test $3.26.
An Altman Z-Score of 0.2 combined with net income falling to $5.9M in FY 2025 signals financial distress risk alongside a 1.22% FCF yie
Here is the bear case nobody on the bull side wants to address on MNKD: An Altman Z-Score of 0.2 combined with net income falling to $5.9M in FY 2025 signals financial distress risk alongside a 1.22% FCF yield.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.